INTRODUCTION: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine. MATERIALS AND METHODS: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data. RESULTS: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04-1.82) times more than that of healthcare workers without COVID-19 like symptoms. CONCLUSIONS: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.

Cochrane Iran Associate Center National Institute for Medical Research Development Tehran Iran

Czech National Center for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Masaryk University Brno Czechia

Department of Economics Jimma University Jimma Ethiopia

Department of Gynecology and Obstetrics Jigjiga University Jigjiga Ethiopia

Department of Health Behavior and Society Jimma University Jimma Ethiopia

Department of Health Policy and Management Jimma University Jimma Ethiopia

Department of Pediatrics and Child Health Jimma University Jimma Ethiopia

Department of Public Health Masaryk University Brno Czechia

Department of Public Health Woldia University Woldia Ethiopia

Gebretsadik Shawo Hospital Southwest Health Bureau Bonga Ethiopia

Institute of Health Information and Statistics of the Czech Republic Prague Czechia

Jigjiga University Specialized Hospital Jigjiga University Jigjiga Ethiopia

Jimma University Medical Center Jimma University Jimma Ethiopia

Seqiz Health Network Kurdistan University of Medical Sciences Seqiz Iran

Zobrazit více v PubMed

World Health Organization. Listings of WHO's Response to COVID-19. (2022). Available online at: https://www.who.int/news/item/29-06-2020-covidtimeline (accessed July 6, 2022).

Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, et al. . Articles interventions to mitigate early spread of SARS-CoV-2 in Singapore : a modeling study. Lancet Infect Dis. (2020) 20:1–11. 10.1016/S1473-3099(20)30162-6 PubMed DOI PMC

Chowdhury R, Luhar S, Khan N, Choudhury SR, Matin I. Long-term strategies to control COVID - 19 in low and middle - income countries : an options overview of community - based, non - pharmacological interventions. Eur J Epidemiol. (2020) 35:743–8. 10.1007/s10654-020-00660-1 PubMed DOI PMC

Agarwal A, Rochweng B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. . A living WHO guideline on drugs for COVID-19. BMJ. (2020) 370:1–19. 10.1136/bmj.m3379 PubMed DOI

Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. (2021) 34:711–33. 10.1007/s13577-021-00512-4 PubMed DOI PMC

Su S, Du L. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. (2021) 19:211–9. 10.1038/s41579-020-00462-y PubMed DOI PMC

Petousis-Harris H. Assessing the safety of COVID-19 vaccines : a primer. Drug Safety. (2020) 43:1205–10. 10.1007/s40264-020-01002-6 PubMed DOI PMC

CGTN. China Donates 300, 000 COVID-19 Vaccine Doses to Ethiopia. CGTN. (2021). Available online at: https://newsaf.cgtn.com/news/2021-08-24/China-donates-300-000-COVID-19-vaccine-doses-to-Ethiopia-12YmdwwM17a/index.html (accessed August 24, 2021).

Embassy in Ethiopia US . The United States Donates 1, 552. 590 Doses of the Pfizer COVID-19 Vaccine to Ethiopia News Events. (2021). Available online at: https://et.usembassy.gov/the-united-states-donates-1552590-doses-of-the-pfizer-covid-19-vaccine-to-ethiopia/ (accessed March 19, 2022).

Angelo AT, Alemayehu DS. Health care wor kers intention to accept COVID-19 vaccine and associated factors in southwestern Ethiopia, 2021. PLoS ONE. (2021) 16:e0257109. 10.1371/journal.pone.0257109 PubMed DOI PMC

Belsti Y, Gela YY, Akalu Y, Dagnew B, Getnet M, Seid MA, et al. . Willingness of Ethiopian population to receive COVID-19 vaccine. J Multidiscip Healthc. (2021) 14:1233–43. 10.2147/JMDH.S312637 PubMed DOI PMC

Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. . COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. (2021) 27:1385–94. 10.1038/s41591-021-01454-y PubMed DOI PMC

Klugar M, Riad A, Mohanan L. COVID-19 vaccine booster hesitancy (VBH) of healthcare workers in czechia: National cross-sectional study. Vaccines. (2021) 9:1–29. 10.3390/vaccines9121437 PubMed DOI PMC

Qunaibi E, Basheti I, Soudy M. Hesitancy of Arab healthcare workers toward COVID-19 vaccination: a large-scale multinational study. Vaccines. (2021) 9:1–13. 10.3390/vaccines9050446 PubMed DOI PMC

Zewude B, Habtegiorgis T, Hizkeal A, Dela T. Perceptions and experiences of COVID-19 vaccine side-effects among healthcare workers in Southern Ethiopia: a cross-sectional study. J Pragmat. (2021) 12:131–45. 10.2147/POR.S344848 PubMed DOI PMC

Solomon Y, Eshete T, Mekasha B. COVID-19 vaccine: side effects after the first dose of theOxford AstraZeneca vaccine among health professionals in Low-income country: Ethiopia. J Multidiscip Healthc. (2021) 14:2577–85. 10.2147/JMDH.S331140 PubMed DOI PMC

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. (2021) 397:99–111. 10.1016/S0140-6736(20)32661-1 PubMed DOI PMC

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. (2008) 61:344–9. 10.1016/j.jclinepi.2007.11.008 PubMed DOI

Riad A, Schünemann H, Attia S, Peričić TP, Žuljević MF, Jürisson M, et al. . COVID-19 vaccines safety tracking (Covast): Protocol of a multi-center prospective cohort study for active surveillance of covid-19 vaccines' side effects. Int J Environ Res Public Health. (2021) 18:7859. 10.3390/ijerph18157859 PubMed DOI PMC

Serwaa D, Osei-Boakye F, Nkansah C, Ahiatrogah S, Lamptey E, Abdulai R, et al. . Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers. Human Vaccines Immunother. (2021) 17:3881–6. 10.1080/21645515.2021.1963600 PubMed DOI PMC

Orebi HA, Emara HE, Alhindi AA, Shahin MR, Hegazy AH, Kabbash IA, et al. . Perceptions and experiences of COVID-19 vaccines' side effects among healthcare workers at an Egyptian University Hospital: a cross-sectional study. Trop Med Health. (2022) 50:1–12. 10.1186/s41182-022-00427-2 PubMed DOI PMC

Riad A, Hocková B, Kantorová L, Slávik R, Spurná L, Stebel A, et al. . Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia. Pharmaceuticals. (2021) 14:873. 10.3390/ph14090873 PubMed DOI PMC

Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. (2021) 10:1428. 10.3390/jcm10071428 PubMed DOI PMC

Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. . Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. (2021) 4:e2140364. 10.1001/jamanetworkopen.2021.40364 PubMed DOI PMC

Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. . High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. Vaccines. (2021) 9:42. 10.3390/vaccines9010042 PubMed DOI PMC

Konu YR, Gbeasor-Komlanvi FA, Yerima M, Sadio AJ, Tchankoni MK, Zida-Compaore WIC, et al. . Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021. Arch Public Health. (2021) 79:1–9. 10.1186/s13690-021-00741-x PubMed DOI PMC

World Health Organization-Ethiopia. 2.2 Million COVID-19 Vaccines Allocated by the COVAX Facility Arrive in Ethiopia, Marking the Start of the Country's COVID-19 Vaccination Campaign (2021). Afro WHO. Available online at: https://www.afro.who.int/news/22-million-covid-19-vaccines-allocated-covax-facility-arrive-ethiopia-marking-start-countrys~ (accessed March 19, 2022).

Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA